RNA Modifying Enzymes Market Size, Share, and Industry Analysis, By Type (Polymerase, {T7 RNA Polymerase, T3 RNA Polymerase, and Others}, Ligase, {T4 RNA ligase 1, T4 RNA ligase 2 and Others}, Nucleuses, {Endonuclease and Exonuclease}, and Others), By Source (Animal and Microbial), By Application (Drug Discovery and Research, Vaccine & Therapeutics Manufacturing), By End-user (Pharmaceutical and Biotechnology Companies, Contract Research Organizations and Contract Development & Manufacturing Organizations (CDMOs), Academic Institutes and Research Centers), and Regional Forecast, 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI114801

RNA Modifying Enzymes Market Overview

The global RNA modifying enzymes market is driven by the rise in research and development activities in the RNA-based therapy sector. Additionally, the increase in scope for vaccine development on viruses such as the coronavirus also supports the growth of the market. The RNA modifying enzymes act as catalysts during the chemical modification of RNA molecules after they are transcribed. Additionally, the RNA modifying enzymes are the specialized proteins used for RNA modification or RNA editing.

For instance, in June 2020, Sarepta Therapeutics, Inc. and Codiak BioSciences, Inc. collaborated and entered into a research agreement to design and develop RNA technologies for neuromuscular diseases. The development of RNA technologies increases the adoption of RNA modifying enzyme products and supports market growth.

RNA Modifying Enzymes Market Driver

Rise in Technological Advancement in Development of RNA Therapeutics Drives Market Growth

The market expansion is primarily driven by the rise in technological development in RNA therapeutics across the globe. The technological advancement enables more manipulation of RNA sequences for therapeutics. Additionally, the key factors contributing to the growth of the market are the rise in research and development activities, government support, etc. Moreover, the rise in the development of RNA-based therapeutics, such as mRNA-based vaccines and other RNA-based drugs, boosts the growth of the market during the forecast period.

For instance, in January 2025, Takara Bio USA Holdings, Inc. acquired Curio Bioscience. This strategic acquisition will enhance Takara Bio’s power as they developed the first commercially available kits for single-cell RNA. This type of innovation and collaboration supports the growth of the market.

Gene Therapy Trials (in Percentage), By Key Countries, 2023

The data in the graph was published in the Journal of Gene Medicine in August 2024. The graph shows that in the U.S., 52.7% of all gene therapy trials were ongoing as of 2023, followed by China at 16.7%.

RNA Modifying Enzymes Market Restraint

Regulatory Hurdles May Hinder Market Growth

The strict rules and regulations regarding new RNA modifications may reduce the growth of the market. The regulatory landscape for RNA-based therapies is complex and time-consuming. The high cost of RNA modifying enzymes limits the adoption of products, which hinders the growth of the market during the forecast period. Moreover, the rise in concern about animal-based RNA modifying enzymes also lowers the growth of the market. The low adoption rate for RNA-based therapeutics may lower the adoption of RNA modifying enzyme products, leading to limiting the market growth.

For instance, according to the data published on Drug Discovery World in September 2024, cancer immunotherapy is a huge advancement in cancer care, and still, many patients are not adopting it. The RNA modifying enzymes are enhancing the results, but the low patient response may hinder the market growth.

RNA Modifying Enzymes Market Opportunity

Rise in Use of Artificial Intelligence (AI) in RNA Therapeutics May Boost Market Growth in Future

In recent years, the rise in the use of AI in research for RNA modifying enzymes, such as RNA editing, mRNA synthesis, etc., has driven the growth of the market in the future. Additionally, after COVID-19, demand for RNA-based vaccines for various diseases has increased, which increases the growth of the market during the forecast period.

For instance, in November 2024, HuidaGene Therapeutics, a global clinical-stage biotechnology company, received the U.S. Food and Drug Administration clearance for HG202. The HG202 is an AI-driven RNA-editing therapy, this type of clearance increases the RNA modification rate, which drives the growth of the market.

Key Insights

The report covers the following key insights:

Overview: Technological Advancements in RNA Modifying Enzymes
Number of Key Procedures, By Key Countries
New Product Launches, By Key Players
Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
Impact of COVID-19 on the Market

Segmentation

By Type	By Source	By Application	By End-user	By Region
Polymerase T7 RNA Polymerase T3 RNA Polymerase Others Ligase T4 RNA ligase 1 T4 RNA ligase 2 Others Nucleuses Endonuclease Exonuclease Others	Animal Microbial	Drug Discovery and Research Vaccine & Therapeutics Manufacturing Others	Pharmaceutical and Biotechnology Companies Contract Research Organizations (CROs) and Contract Development & Manufacturing Organizations (CDMOs) Academic Institutes and Research Centers Others	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Analysis by Type

Based on the type, the market is segmented into polymerase, ligase, nucleuses, and others. The ligase segment is expected to grow significantly during the forecast period. The ligase segment is further sub-segmented into T4 RNA ligase 1, T4 RNA ligase 2, and others. The rise in demand for ligase in synthetic biology and genetic engineering augments the growth of the segment. Additionally, the ligase plays an important role in RNA synthesis and modification processes, which also boosts the market growth.

For instance, in 2023, Thermo Fisher Scientific Inc. introduced a new line of CRISPR-associated enzymes. TrueCut Cas9 proteins are designed for high CRISPR editing efficiency across a range of gene targets. The TrueCut Cas9 proteins must be combined with a guide RNA (gRNA) to produce a functional, target-specific editing complex.

Analysis by Source

Based on the source, the market is segmented into animal and microbial. The microbial segment held a significant share of the market in 2024. The significant share of the segment is due to the efficiency and versatility of enzymes produced by microorganisms, specifically bacteria and fungi. Additionally, the microbial source is cost-effective and has a high enzyme yield, which increases the growth of the segment during the forecast period.

For instance, in March 2024, Takara Bio Inc. launched the T7 RNA Polymerase version.2.0 RNA polymerase, which is suitable for the development of mRNA vaccines and therapeutics. The new product launches drive the growth of the market.

Analysis by Application

By application, the market is divided into drug discovery and research, vaccine & therapeutics manufacturing, and others.

The vaccine & therapeutics manufacturing segment held a significant portion of the market. The growth of the segment is attributed to the rise in demand for RNA-based vaccines for the treatment of rare diseases. Additionally, after COVID-19, the demand for mRNA-based therapeutics and vaccines is rising, which supports the growth of the market.

For instance, according to the data published by the World Health Organization (WHO) in July 2024, new initiatives have been launched for the development of an advanced mRNA vaccine against human avian influenza (H5N1). The initiatives and new projects on RNA-based therapeutics raise the adoption of RNA modifying enzymes and drive market growth.

Analysis by End-user

By end-user, the market is divided into pharmaceutical and biotechnology companies, contract research organizations (CROs) and contract development & manufacturing organizations (CDMOs), academic institutes and research centers, and others.

The pharmaceutical and biotechnology companies segment accounted for the major portion of the market in 2024. The growth can be attributed to the rise in the utilization of RNA modifying enzymes for the development of RNA technologies such as mRNA vaccines.

For instance, according to the data published on Express Healthcare in April 2025, Southern RNA is an Australian innovative biotechnology company specializing in producing RNA-based products, therapeutics, and technologies. These types of biotech and pharma companies boost the segment and market growth.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization to gain extensive market insights.

North America accounted for a substantial share of the global RNA modifying enzymes market in 2024. The strong presence of advanced research facilities and infrastructure augments the region's growth. Additionally, the presence of key market players in this region also boosts the growth of the market. Moreover, government support and high investment in biotechnology research also drive the growth of RNA modifying enzymes market.

For instance, in July 2024, AIRNA, a biotech startup, raised a USD 60 million oversubscribed financing round, which brings the total Series A funding to USD 90 million for the advanced new class of RNA editing medicines. This type of investment boosts the growth of the global RNA modifying enzymes market in this region.

Europe held a substantial share of the global RNA modifying enzymes market. The growth of the region can be attributed to several established research institutions and the rise in focus on mRNA technology. Additionally, the rapid adoption rate for new products and technology also drives the market growth in this region.

For instance, in June 2021, Arrowhead Pharmaceuticals Inc. collaborated with Horizon Therapeutics plc to develop Arrowhead's ribonucleic acid interference (RNAi) therapy, ARO-XDH. This collaboration supports the market growth during the forecast period.

The Asia Pacific region is experiencing rapid growth in the RNA modifying enzymes market, driven by rising awareness of RNA-based therapeutics.

Key Players Covered

The global RNA modifying enzymes market is partially consolidated with a few key players. The report will include the profiles of the following key players:

QIAGEN (Germany)
Thermo Fisher Scientific, Inc. (U.S.)
New England Biolabs, Inc. (U.S.)
Fortis Life Sciences, LLC. (U.S.)
Promega Corporation (U.S.)
Takara Bio Inc. (Japan)
Agilent Technologies, Inc. (U.S.)
Other Prominent Players

Key Industry Developments

In September 2024, HAYA Therapeutics SA collaborated with Eli Lilly and Company, and this collaboration is worth up to USD 1 billion, aims to develop RNA-based drug targets to support preclinical drug discovery efforts in obesity and metabolic conditions using HAYA’s regulatory genome platform.
In April 2020, Blackstone and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, entered into a strategic collaboration in which Blackstone will provide USD 2 billion in support of Alnylam’s advancement of innovative RNA interference (RNAi) medicines, which will improve the quality of life of patients suffering from a range of debilitating diseases.